TB-500

Research

Thymosin Beta-4 Fragment

Aliases
Thymosin β4, Tβ4
Administration
Subcutaneous injection, Intramuscular injection

Research and regulatory

Development stage

Phase II trials (cardiac); preclinical others.

Legal and regulatory

Unscheduled research compound; not FDA approved. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend TB-500 for the 503A Bulks List, which would make it eligible for pharmacy compounding — this is a recommendation only, not yet legal to compound, pending formal FDA rulemaking.

Side effects

Fatigue, transient head rush; well-tolerated